Who
Andrew Reardon
CLO & Secretary
Company insider
Files Form 4 as: CLO & Secretary, Ligand Pharmaceuticals.
In numbers
- Trades disclosed
- 193
- Buys
- 0
- Sells
- 15
- Bought
- $0
- Sold
- $20.5M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Nov 2022
- Last trade
- 2 Oct 2026
- Last filed
- 6 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $18K340 at $52.27 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $252K833 at $302.51 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $600K1,976 at $303.54 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $467K1,535 at $304.52 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $124K404 at $306.18 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $72K235 at $307.19 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $5,23217 at $307.74 | filing |
| 2 Oct 2026filed 6 Oct 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —340 at $0.00 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $85K300 at $283.99 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $513K1,800 at $285.17 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $606K2,115 at $286.36 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $111K385 at $287.53 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $116K400 at $288.98 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $85K300 at $283.99 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $513K1,800 at $285.17 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $606K2,115 at $286.36 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $111K385 at $287.53 | filing |
| 3 Sep 2026filed 8 Sep 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $116K400 at $288.98 | filing |
| 3 Aug 2026filed 4 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $261K5,000 at $52.27 | filing |
| 3 Aug 2026filed 4 Aug 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $289K991 at $291.71 | filing |
News
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)LGND · tickerreport.com · 23 Oct 2026
0 headlines in the last 90 days name Andrew Reardon; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.